Efficacy of using synbiotics during neoadjuvant chemotherapy in esophageal cancer patients

INTERVENTION: Yakult BL Seichoyaku (Yakult Honsha, Japan) galactoorigosaccharides (Oligomate S‐HP, Yakult Honsha, Japan) Biofermin CONDITION: esophageal cancer PRIMARY OUTCOME: Incidence of adverse events during chemotherapy SECONDARY OUTCOME: Nutritional parameter, fecal microflora, fecal organic acid INCLUSION CRITERIA: Patients with histologically confirmed primary esophageal cancer, who are scheduled to receive neoadjuvant chemotherapy ‐Performance status is 0‐2 ‐No serious abnormality in heart, lung, bone marrow, liver, and renal functions